TG Therapeutics is savoring positive trial data on its investigational TG-1101 in high risk CCL - but that could be soured next year by a little known mid-stage trial of Imbruvica plus Rituxan.
Positive top line data for TG Therapeutics Inc.' Phase III GENUINE study of TG-1101 (ublituximab, a monoclonal antibody that targets CD20) plus Imbruvica (ibrutinib) versus Imbruvica alone in previously treated patients with high-risk r/r CLL were welcomed by analysts and investors alike, ensuring the company's share price almost doubled within a week.
The trial met its primary endpoint of increasing overall response rate
Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.
BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.
A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.
Company surprises investors with Jørgensen's exit but insists its strategy will not change.
Company surprises investors with Jørgensen's exit but insists its strategy will not change.
The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.
Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.
